Exact Sciences Corporation (EXAS)
Largest Insider Buys in Sector
EXAS Stock Price History Chart
EXAS Stock Performance
About Exact Sciences Corporation
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX …
Insider Activity of Exact Sciences Corporation
Over the last 12 months, insiders at Exact Sciences Corporation have bought $0 and sold $6.7M worth of Exact Sciences Corporation stock.
On average, over the past 5 years, insiders at Exact Sciences Corporation have bought $0 and sold $26.25M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $188,550 was made by Carey Thomas D. (director) on 2017‑08‑17.
List of Insider Buy and Sell Transactions, Exact Sciences Corporation
| 2024-10-08 | Sale | EVP, GM, Precision Oncology | 929 0.0005% | $70.00 | $65,030 | +1.90% | ||
| 2024-09-18 | Sale | EVP, GM, Precision Oncology | 929 0.0005% | $70.00 | $65,030 | +0.39% | ||
| 2024-05-01 | Sale | President and CEO | 1,155 0.0006% | $60.15 | $69,473 | -3.11% | ||
| 2024-05-01 | Sale | EVP, Human Resources | 102 <0.0001% | $60.15 | $6,135 | -3.11% | ||
| 2024-05-01 | Sale | Chief Commercial Officer | 136 <0.0001% | $60.15 | $8,180 | -3.11% | ||
| 2024-05-01 | Sale | director | 67 <0.0001% | $60.15 | $4,030 | -3.11% | ||
| 2024-05-01 | Sale | General Manager, Screening | 102 <0.0001% | $60.15 | $6,135 | -3.11% | ||
| 2024-05-01 | Sale | EVP, GM., Precision Oncology | 110 <0.0001% | $60.15 | $6,617 | -3.11% | ||
| 2024-05-01 | Sale | Chief Financial Officer | 136 <0.0001% | $60.15 | $8,180 | -3.11% | ||
| 2024-05-01 | Sale | SVP, General Counsel & Sec | 30 <0.0001% | $60.15 | $1,805 | -3.11% | ||
| 2024-04-02 | Sale | EVP, GM., Precision Oncology | 924 0.0005% | $79.43 | $73,393 | -19.41% | ||
| 2024-04-01 | Sale | EVP, Human Resources | 2,000 0.0011% | $70.00 | $140,000 | -15.42% | ||
| 2024-03-28 | Sale | EVP, Human Resources | 2,000 0.0011% | $70.00 | $140,000 | -13.58% | ||
| 2024-03-01 | Sale | President and CEO | 8,271 0.0046% | $59.32 | $490,636 | +0.85% | ||
| 2024-03-01 | Sale | EVP, Human Resources | 1,724 0.0009% | $59.32 | $102,268 | +0.85% | ||
| 2024-03-01 | Sale | director | 2,000 0.0011% | $57.50 | $115,000 | +0.85% | ||
| 2024-03-01 | Sale | Chief Commercial Officer | 2,412 0.0013% | $59.32 | $143,080 | +0.85% | ||
| 2024-03-01 | Sale | director | 5,000 0.0027% | $57.50 | $287,500 | +0.85% | ||
| 2024-03-01 | Sale | General Manager, Screening | 2,154 0.0012% | $59.32 | $127,775 | +0.85% | ||
| 2024-03-01 | Sale | Gen. Mgr., Precision Oncology | 2,323 0.0013% | $59.32 | $137,800 | +0.85% |
Insider Historical Profitability
| Conroy Kevin T | President and CEO | 1156191 0.6257% | $54.98 | 6 | 72 | +71.25% |
| Doyle James Edward | director | 50110 0.0271% | $54.98 | 1 | 12 | +138.27% |
| LEVANGIE DANIEL J | director | 22975 0.0124% | $54.98 | 1 | 3 | +50.94% |
| ARORA MANEESH | COO | 645089 0.3491% | $54.98 | 3 | 24 | +31.72% |
| THOMPSON DAVID | director | 136379 0.0738% | $54.98 | 3 | 0 | +87.45% |
Institutional Investor Ownership
| The Vanguard Group | $1.23B | 9.61 | 17.74M | +1.03% | +$12.45M | 0.02 | |
| Capital World Investors | $899.53M | 7.06 | 13.03M | +74.41% | +$383.78M | 0.15 | |
| JPMorgan Chase | $855.27M | 6.71 | 12.38M | -25.8% | -$297.39M | 0.08 | |
| BlackRock | $785.63M | 6.17 | 11.38M | +2.92% | +$22.31M | 0.02 | |
| Wellington Management Company | $737.55M | 5.79 | 10.68M | +3.88% | +$27.56M | 0.13 |